Preoperative pazopanib in high-risk soft tissue sarcoma: phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04)

BackgroundPreoperative devascularization might improve local control and thus the outcome of patients with soft tissue sarcoma (STS). The multikinase inhibitor pazopanib has antiangiogenic effects and is approved for treating metastatic STS. We conducted a trial of preoperative pazopanib therapy in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ronellenfitsch, Ulrich (VerfasserIn) , Karampinis, Ioannis (VerfasserIn) , Jakob, Jens (VerfasserIn) , Kasper, Bernd (VerfasserIn) , Nowak, Kai (VerfasserIn) , Pilz, Lothar R. (VerfasserIn) , Attenberger, Ulrike (VerfasserIn) , Gaiser, Timo (VerfasserIn) , Hohenberger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 6 March 2019
In: Annals of surgical oncology
Year: 2019, Jahrgang: 26, Heft: 5, Pages: 1332-1339
ISSN:1534-4681
DOI:10.1245/s10434-019-07183-4
Online-Zugang:Verlag, Volltext: https://doi.org/10.1245/s10434-019-07183-4
Volltext
Verfasserangaben:Ulrich Ronellenfitsch, Ioannis Karampinis, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar Pilz, Ulrike Attenberger, Timo Gaiser, Hans-Günther Derigs, Matthias Schwarzbach, and Peter Hohenberger

MARC

LEADER 00000caa a2200000 c 4500
001 1665336366
003 DE-627
005 20220816151551.0
007 cr uuu---uuuuu
008 190514s2019 xx |||||o 00| ||eng c
024 7 |a 10.1245/s10434-019-07183-4  |2 doi 
035 |a (DE-627)1665336366 
035 |a (DE-599)KXP1665336366 
035 |a (OCoLC)1341212833 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ronellenfitsch, Ulrich  |d 1977-  |e VerfasserIn  |0 (DE-588)13178322X  |0 (DE-627)513952179  |0 (DE-576)29874144X  |4 aut 
245 1 0 |a Preoperative pazopanib in high-risk soft tissue sarcoma  |b phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04)  |c Ulrich Ronellenfitsch, Ioannis Karampinis, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar Pilz, Ulrike Attenberger, Timo Gaiser, Hans-Günther Derigs, Matthias Schwarzbach, and Peter Hohenberger 
264 1 |c 6 March 2019 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.05.2019 
520 |a BackgroundPreoperative devascularization might improve local control and thus the outcome of patients with soft tissue sarcoma (STS). The multikinase inhibitor pazopanib has antiangiogenic effects and is approved for treating metastatic STS. We conducted a trial of preoperative pazopanib therapy in high-risk STS.MethodsThis single-arm, phase II trial included patients with resectable, non-metastatic, treatment-naïve, high-risk STS. Patients received pazopanib 800 mg daily while waiting for surgery (21-day ‘window of opportunity’). The primary endpoint was metabolic response rate (MRR; proportion of patients with ≥ 50% reduction of mean standardized uptake value [SUVmean] in post- vs. pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography [FDG-PET-CT]). Planned sample size was 35 patients (type I error, 5%; type II error, 20%). A translational substudy explored associations between response and concentration of circulating angiogenic factors.ResultsFutility analysis was performed after 21 patients (11 female, mean age 67 years; liposarcoma n = 15); 17/21 patients were evaluable for the primary endpoint. The MRR was 1/17 (5.9%, 95% confidence interval < 0.01-0.29). Mean change in SUVmean of post- versus pretreatment PET was a 6% decrease (range 65% decrease to 34% increase); 7/21 (33.3%) patients had 12 grade 3/4 toxicities, and 19/21 (95.2%) patients were resected (all R0). One (4.8%) patient suffered a grade 4 postoperative complication (anastomotic leakage). Circulating endothelial progenitor cells, soluble vascular endothelial growth factor, and angiopoietin-2 concentrations showed no relevant changes during treatment.ConclusionsAlthough this study showed that preoperative pazopanib is not effective for unselected high-risk STS patients, relevant treatment effects were observed in a single patient. Future research needs to better define subgroups potentially benefiting from preoperative pazopanib treatment.ClinicalTrials.gov identifierNCT01543802. 
700 1 |a Karampinis, Ioannis  |d 1987-  |e VerfasserIn  |0 (DE-588)105281896X  |0 (DE-627)789073625  |0 (DE-576)408548606  |4 aut 
700 1 |a Jakob, Jens  |d 1974-  |e VerfasserIn  |0 (DE-588)129491128  |0 (DE-627)470196335  |0 (DE-576)297687794  |4 aut 
700 1 |a Kasper, Bernd  |d 1974-  |e VerfasserIn  |0 (DE-588)12274764X  |0 (DE-627)082130736  |0 (DE-576)29340447X  |4 aut 
700 1 |a Nowak, Kai  |d 1973-  |e VerfasserIn  |0 (DE-588)124774067  |0 (DE-627)366045180  |0 (DE-576)294495045  |4 aut 
700 1 |a Pilz, Lothar R.  |d 1954-  |e VerfasserIn  |0 (DE-588)1036758621  |0 (DE-627)751686107  |0 (DE-576)38680799X  |4 aut 
700 1 |a Attenberger, Ulrike  |d 1980-  |e VerfasserIn  |0 (DE-588)131554859  |0 (DE-627)510698557  |0 (DE-576)298582775  |4 aut 
700 1 |a Gaiser, Timo  |d 1975-  |e VerfasserIn  |0 (DE-588)1030402280  |0 (DE-627)735221685  |0 (DE-576)378226533  |4 aut 
700 1 |a Hohenberger, Peter  |d 1953-  |e VerfasserIn  |0 (DE-588)1025311469  |0 (DE-627)72202875X  |0 (DE-576)370195574  |4 aut 
773 0 8 |i Enthalten in  |t Annals of surgical oncology  |d Berlin [u.a.] : Springer, 1994  |g 26(2019), 5, Seite 1332-1339  |h Online-Ressource  |w (DE-627)343969947  |w (DE-600)2074021-9  |w (DE-576)099879212  |x 1534-4681  |7 nnas  |a Preoperative pazopanib in high-risk soft tissue sarcoma phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04) 
773 1 8 |g volume:26  |g year:2019  |g number:5  |g pages:1332-1339  |g extent:8  |a Preoperative pazopanib in high-risk soft tissue sarcoma phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04) 
856 4 0 |u https://doi.org/10.1245/s10434-019-07183-4  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1245/s10434-019-07183-4  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190514 
993 |a Article 
994 |a 2019 
998 |g 1025311469  |a Hohenberger, Peter  |m 1025311469:Hohenberger, Peter  |d 60000  |d 61800  |e 60000PH1025311469  |e 61800PH1025311469  |k 0/60000/  |k 1/60000/61800/  |p 13  |y j 
998 |g 1030402280  |a Gaiser, Timo  |m 1030402280:Gaiser, Timo  |d 60000  |d 63400  |e 60000PG1030402280  |e 63400PG1030402280  |k 0/60000/  |k 1/60000/63400/  |p 10 
998 |g 131554859  |a Attenberger, Ulrike  |m 131554859:Attenberger, Ulrike  |d 60000  |d 62900  |e 60000PA131554859  |e 62900PA131554859  |k 0/60000/  |k 1/60000/62900/  |p 9 
998 |g 1036758621  |a Pilz, Lothar R.  |m 1036758621:Pilz, Lothar R.  |d 60000  |e 60000PP1036758621  |k 0/60000/  |p 8 
998 |g 124774067  |a Nowak, Kai  |m 124774067:Nowak, Kai  |d 60000  |e 60000PN124774067  |k 0/60000/  |p 7 
998 |g 12274764X  |a Kasper, Bernd  |m 12274764X:Kasper, Bernd  |d 60000  |e 60000PK12274764X  |k 0/60000/  |p 6 
998 |g 129491128  |a Jakob, Jens  |m 129491128:Jakob, Jens  |d 60000  |d 61800  |e 60000PJ129491128  |e 61800PJ129491128  |k 0/60000/  |k 1/60000/61800/  |p 5 
998 |g 105281896X  |a Karampinis, Ioannis  |m 105281896X:Karampinis, Ioannis  |d 60000  |e 60000PK105281896X  |k 0/60000/  |p 2 
998 |g 13178322X  |a Ronellenfitsch, Ulrich  |m 13178322X:Ronellenfitsch, Ulrich  |d 910000  |d 910200  |d 50000  |e 910000PR13178322X  |e 910200PR13178322X  |e 50000PR13178322X  |k 0/910000/  |k 1/910000/910200/  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1665336366  |e 3475647966 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 14.05.2019"],"relHost":[{"title":[{"title_sort":"Annals of surgical oncology","title":"Annals of surgical oncology","subtitle":"the official journal of the Society of Surgical Oncology"}],"pubHistory":["1.1994 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 26.09.25"],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"Society of Surgical Oncology"}],"part":{"pages":"1332-1339","volume":"26","extent":"8","text":"26(2019), 5, Seite 1332-1339","year":"2019","issue":"5"},"origin":[{"dateIssuedDisp":"1994-","publisher":"Springer ; Lippincott Williams & Wilkins","dateIssuedKey":"1994","publisherPlace":"Berlin [u.a.] ; Philadelphia, Pa."}],"id":{"zdb":["2074021-9"],"issn":["1534-4681"],"eki":["343969947"]},"disp":"Preoperative pazopanib in high-risk soft tissue sarcoma phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04)Annals of surgical oncology","recId":"343969947"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"8 S."}],"title":[{"title_sort":"Preoperative pazopanib in high-risk soft tissue sarcoma","subtitle":"phase II window-of opportunity study of the german interdisciplinary sarcoma group (NOPASS/GISG-04)","title":"Preoperative pazopanib in high-risk soft tissue sarcoma"}],"person":[{"display":"Ronellenfitsch, Ulrich","family":"Ronellenfitsch","role":"aut","given":"Ulrich"},{"display":"Karampinis, Ioannis","role":"aut","given":"Ioannis","family":"Karampinis"},{"family":"Jakob","given":"Jens","role":"aut","display":"Jakob, Jens"},{"display":"Kasper, Bernd","family":"Kasper","given":"Bernd","role":"aut"},{"display":"Nowak, Kai","family":"Nowak","given":"Kai","role":"aut"},{"family":"Pilz","given":"Lothar R.","role":"aut","display":"Pilz, Lothar R."},{"family":"Attenberger","role":"aut","given":"Ulrike","display":"Attenberger, Ulrike"},{"role":"aut","given":"Timo","family":"Gaiser","display":"Gaiser, Timo"},{"given":"Peter","role":"aut","family":"Hohenberger","display":"Hohenberger, Peter"}],"recId":"1665336366","name":{"displayForm":["Ulrich Ronellenfitsch, Ioannis Karampinis, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar Pilz, Ulrike Attenberger, Timo Gaiser, Hans-Günther Derigs, Matthias Schwarzbach, and Peter Hohenberger"]},"origin":[{"dateIssuedDisp":"6 March 2019","dateIssuedKey":"2019"}],"id":{"eki":["1665336366"],"doi":["10.1245/s10434-019-07183-4"]}} 
SRT |a RONELLENFIPREOPERATI6201